These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 23089757)

  • 1. Innate aminoglycoside resistance of Achromobacter xylosoxidans is due to AxyXY-OprZ, an RND-type multidrug efflux pump.
    Bador J; Amoureux L; Blanc E; Neuwirth C
    Antimicrob Agents Chemother; 2013 Jan; 57(1):603-5. PubMed ID: 23089757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of AxyZ Transcriptional Regulator in Overproduction of AxyXY-OprZ Multidrug Efflux System in Achromobacter Species Mutants Selected by Tobramycin.
    Bador J; Neuwirth C; Grangier N; Muniz M; Germé L; Bonnet J; Pillay VG; Llanes C; de Curraize C; Amoureux L
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28584156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First description of an RND-type multidrug efflux pump in Achromobacter xylosoxidans, AxyABM.
    Bador J; Amoureux L; Duez JM; Drabowicz A; Siebor E; Llanes C; Neuwirth C
    Antimicrob Agents Chemother; 2011 Oct; 55(10):4912-4. PubMed ID: 21807978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AcGI1, a novel genomic island carrying antibiotic resistance integron In687 in multidrug resistant Achromobacter xylosoxidans in a teaching hospital in Thailand.
    Pongchaikul P; Santanirand P; Antonyuk S; Winstanley C; Darby AC
    FEMS Microbiol Lett; 2020 Jul; 367(14):. PubMed ID: 32592387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Achromobacter xylosoxidans respiratory tract infections in cystic fibrosis patients.
    Raso T; Bianco O; Grosso B; Zucca M; Savoia D
    APMIS; 2008 Sep; 116(9):837-41. PubMed ID: 19024606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pan-Resistant Achromobacter xylosoxidans and Stenotrophomonas maltophilia Infection in Cystic Fibrosis Does Not Reduce Survival After Lung Transplantation.
    Lobo LJ; Tulu Z; Aris RM; Noone PG
    Transplantation; 2015 Oct; 99(10):2196-202. PubMed ID: 25856407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluoroquinolone-resistant Achromobacter xylosoxidans clinical isolates from Serbia: high prevalence of the aac-(6')-Ib-cr gene among resistant isolates.
    Lilić B; Filipić B; Malešević M; Novović K; Vasiljević Z; Kojić M; Jovčić B
    Folia Microbiol (Praha); 2019 Mar; 64(2):153-159. PubMed ID: 30105450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic insights into intrinsic and acquired drug resistance mechanisms in Achromobacter xylosoxidans.
    Hu Y; Zhu Y; Ma Y; Liu F; Lu N; Yang X; Luan C; Yi Y; Zhu B
    Antimicrob Agents Chemother; 2015 Feb; 59(2):1152-61. PubMed ID: 25487802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Achromobacter xylosoxidans: an emerging pathogen carrying different elements involved in horizontal genetic transfer.
    Traglia GM; Almuzara M; Merkier AK; Adams C; Galanternik L; Vay C; Centrón D; Ramírez MS
    Curr Microbiol; 2012 Dec; 65(6):673-8. PubMed ID: 22926720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal Surveillance and Combination Antimicrobial Susceptibility Testing of Multidrug-Resistant
    Okoliegbe IN; Hijazi K; Cooper K; Ironside C; Gould IM
    Antimicrob Agents Chemother; 2020 Oct; 64(11):. PubMed ID: 32816722
    [No Abstract]   [Full Text] [Related]  

  • 11. Properties of Achromobacter xylosoxidans highly resistant to aminoglycoside antibiotics.
    Nakamoto S; Goda N; Hayabuchi T; Tamaki H; Ishida A; Suzuki A; Nakano K; Yui S; Katsumata Y; Yamagami Y; Burioka N; Chikumi H; Shimizu E
    Jpn J Antibiot; 2016 Apr; 69(2):113-8. PubMed ID: 27544979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of AxyABM overexpression in acquired resistance in Achromobacter xylosoxidans.
    Magallon A; Amoureux L; Garrigos T; Sonois M; Varin V; Neuwirth C; Bador J
    J Antimicrob Chemother; 2022 Mar; 77(4):926-929. PubMed ID: 35029278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationships between antimicrobial use and antimicrobial resistance in Gram-negative bacteria causing nosocomial infections from 1991-2003 at a university hospital in Taiwan.
    Hsueh PR; Chen WH; Luh KT
    Int J Antimicrob Agents; 2005 Dec; 26(6):463-72. PubMed ID: 16280243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distribution of innate efflux-mediated aminoglycoside resistance among different Achromobacter species.
    Bador J; Neuwirth C; Liszczynski P; Mézier MC; Chrétiennot M; Grenot E; Chapuis A; de Curraize C; Amoureux L
    New Microbes New Infect; 2016 Mar; 10():1-5. PubMed ID: 26904200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study of 109 Achromobacter spp. isolates from 9 French CF centres reveals the circulation of a multiresistant clone of A. xylosoxidans belonging to ST 137.
    Amoureux L; Sauge J; Sarret B; Lhoumeau M; Bajard A; Tetu J; Bador J; Neuwirth C;
    J Cyst Fibros; 2019 Nov; 18(6):804-807. PubMed ID: 31104975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular characterization of IMP-type metallo-β-lactamases among multidrug-resistant Achromobacter xylosoxidans.
    Yamamoto M; Nagao M; Hotta G; Matsumura Y; Matsushima A; Ito Y; Takakura S; Ichiyama S
    J Antimicrob Chemother; 2012 Sep; 67(9):2110-3. PubMed ID: 22577105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic Airway Colonization by Achromobacter xylosoxidans in Cystic Fibrosis Patients Is Not Sustained by Their Domestic Environment.
    Dupont C; Jumas-Bilak E; Doisy C; Aujoulat F; Chiron R; Marchandin H
    Appl Environ Microbiol; 2018 Dec; 84(23):. PubMed ID: 30217850
    [No Abstract]   [Full Text] [Related]  

  • 18. Structured surveillance of Achromobacter, Pandoraea and Ralstonia species from patients in England with cystic fibrosis.
    Coward A; Kenna DTD; Woodford N; Turton JF;
    J Cyst Fibros; 2020 May; 19(3):388-393. PubMed ID: 31862307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiology and resistance of Achromobacter xylosoxidans from cystic fibrosis patients in Dijon, Burgundy: first French data.
    Amoureux L; Bador J; Siebor E; Taillefumier N; Fanton A; Neuwirth C
    J Cyst Fibros; 2013 Mar; 12(2):170-6. PubMed ID: 22944724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of β-lactams in combination with avibactam against multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Achromobacter xylosoxidans isolates from patients with cystic fibrosis.
    Mathy V; Grohs P; Compain F
    J Med Microbiol; 2018 Sep; 67(9):1217-1220. PubMed ID: 30016231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.